{
    "clinical_study": {
        "@rank": "16867", 
        "brief_summary": {
            "textblock": "Long term use of bronchodilators in CF is beneficial to the improvement of pulmonary\n      function and symptoms. This study is investigating the long-term benefit of administration\n      of the drug Salmeterol, a bronchodilator.  Salmeterol will be compared to albuterol or\n      placebo. The medication will be inhaled twice a day for 6 months."
        }, 
        "brief_title": "A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis", 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients that have been diagnosed with cystic fibrosis and are above 5 years and below 45\n      years of age are eligible. Subjects will be randomized into 1 of 3 groups.  One group will\n      get Salmeterol by multi-dose inhaler (MDI) 2 puffs 2 times a day, one group will get\n      albuterol by MDI 2 puffs 2 times a day and the other will get placebo by MDI 2 puffs 2 times\n      a day.  Height and weight along with pulmonary function testing and vital signs will be\n      monitored at the beginning of the study and at Visits 2, 3, and 4.  Peak flow monitoring\n      will be done each morning before study medication at home.  A daily diary will be kept of\n      this measurement. Subjects will be seen in the research center at visits 1,2,3, and 4.\n      Telephone contact will be done at Day 15, 60, 120, and 150.  Individual outcomes include a\n      potential increase in pulmonary function testing and a decrease in frequency of pulmonary\n      exacerbations, hospitalizations, and usage of antibiotics."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to perform reproducible spirometry\n\n          -  FEVI > 50% and < 90% (Knudsen)\n\n          -  A CF pulmonary exacerbation within the last year or an FEVI<80%\n\n          -  At least one delta f508 allele on CF mutation analysis\n\n          -  Ability to demonstrate use of inhaled medicine and FEVI and PEFR monitor\n\n          -  Written informed consent\n\n          -  Negative serum pregnancy test on enrollment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "45 Years", 
            "minimum_age": "5 Years"
        }, 
        "firstreceived_date": "April 13, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00005110", 
            "org_study_id": "NCRR-M01RR00036-5074", 
            "secondary_id": "M01RR00036"
        }, 
        "intervention": [
            {
                "intervention_name": "Salmeterol", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Albuterol", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Albuterol", 
                "Salmeterol"
            ]
        }, 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Division of Allergy and Pulmonary Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Suspended", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00005110"
        }, 
        "source": "National Center for Research Resources (NCRR)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Center for Research Resources (NCRR)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2001"
    }, 
    "geocoordinates": {
        "Division of Allergy and Pulmonary Medicine": "38.627 -90.199"
    }
}